Abstract:Patients with head and neck cancer receiving chemo-radiation therapy/radiation therapy often develop oral mucositis (OM) that may interference with quality of life and lead to unplanned treatment interruptions, which may severely reduce rates of locoregional tumor control and survival. We hypothesize that EGCG is safe and effective in treating radiation OM and conducted a phase I trial testing this hypothesis with patients undergoing radiotherapy. All the patients underwent intensity modulation radiation therapy (total dose, 66-72Gy). Eligible patients were also required to have met the following criteria: age≥18 years; ECOG PS 0-1; head and neck cancer; received at least 60 Gy or more for oral mucosa. Five dose levels for EGCG were defined as following: 440 μmol/L, 880 μmol/L, 1320 μmol/L, 1760 μmol/L and 2200 μmol/L. Immediately after the documentation of Grade I OM, the EGCG solution was given during radiation therapy and for additional 2 weeks after radiation therapy was completed. Outcome measures were assessed using observer-assessment scores that were defined by World Health Organization (WHO) scores and Oral Mucosal Assessment Scale (OMAS) and self-assessment scores that evaluated symptoms according to patient satisfaction tool (PST) and numerical rating scale (NRS). 20 patients completed the course of therapy per study protocol and RT was not interrupted. The early WHO Grade 1 radiation mucositis appeared in 12 patients during the second week with the remainder during the third week after RT initiated. In addition, the median duration of EGCG treating time is 7 weeks. Burning and nausea were the most common toxicities. One of 6 patients at dose level 2 (880μmol/L) and two of five patients at dose level 5 (2200μmol/L) developed Grade 2 burning or nausea. The maximum tolerated dose of EGCG concentration was 2200μmol/L. Only 29.4% patients experienced WHO Grade 2 mucositis as the highest grade at the end of radiation therapy. Despite lack of an exact test for the binomial distribution, it was apparently lower compared with a historical rate of Grade 3-4 (34%). The maximum OMAS score appeared in 7 of 17 patients with Grade 1 and the rest 10 patients with Grade 2. Roughly 50% of patients reported that EGCG had not improved their symptoms through the PST weekly. The difference was statistically significant in term of patient-reported pain score related to oral mucositis between at the beginning of EGCG and the end of RT (t = 3.833, P = 0.001), even during the different EGCG dose period. Similarly, the pain scores not only between onset of EGCG application and first week after RT, but also between onset of EGCG application and second week after RT on the NRS diary were statistically different (t = 4.667, P < 0.001; t = 9.109, P < 0.001). The main dose-limiting toxicities for EGCG mouthwash are burning and nausea, the recommended dose for phase II study is 1760μmol/L, and EGCG has the protection capability in mucosa exposed to radiation.

Evaluation of Epigallocatechin-3-Gallate as a Radioprotective Agent During Radiotherapy of Lung Cancer Patients: A 5-Year Survival Analysis of a Phase 2 Study

Efficacy of Oral Epigallocatechin-3-gallate Solution Administration During Radiotherapy for Non-Small-cell Lung Cancer Patients: A Long-Term Observational Study

A Prospective, Three-Arm, Randomized Trial of EGCG for Preventing Radiation-Induced Esophagitis in Lung Cancer Patients Receiving Radiotherapy

A phase I study of concurrent chemotherapy and thoracic radiotherapy with oral epigallocatechin-3-gallate protection in patients with locally advanced stage III non-small-cell lung cancer

Oral Epigallocatechin-3-Gallate Treats Acute Radiation-Induced Esophagitis in Patients with Esophageal Cancer Receiving Chemoradiation Therapy/Radiation Therapy

A Prospective Phase II Trial of EGCG in Treatment of Acute Radiation-Induced Esophagitis for Stage III Lung Cancer

Phase II Trial of Epigallocatechin-3-Gallate in Acute Radiation-Induced Esophagitis for Esophagus Cancer.

A Randomized, Double-blind, Placebo-controlled Phase 2 Trial of Epigallocatechin-gallate in the Prevention of Radiation-induced Dermatitis

Epigallocatechin-3-gallate mouthwash protects mucosa from radiation-induced mucositis in head and neck cancer patients: a prospective, non-randomised, phase 1 trial

Concurrent Erlotinib and Radiation Therapy for Chemoradiation Therapy–Intolerant Esophageal Squamous Cell Carcinoma Patients: an Updated Result

Survival benefit of thoracic radiotherapy plus EGFR-TKIs in patients with non-oligometastatic advanced non-small-cell lung cancer: a single-center retrospective study

Phase I study of topical epigallocatechin-3-gallate (EGCG) in patients with breast cancer receiving adjuvant radiotherapy

Epigallocatechin-3-Gallate Mouthwash Mitigates Oral Mucositis in Patients with Head and Neck Cancer Receiving Chemoradiation Therapy/Radiation Therapy

Trial of Assessing the Effectiveness of Topical Epigallocatechin-3-Gallate As an Interventional Agent for Radiation-Induced Acute Skin Toxicity to the Breast in Women Undergoing Adjuvant Radiation Therapy

Epigallocatechin-3-gallate ameliorates radiation-induced acute skin damage in breast cancer patients undergoing adjuvant radiotherapy

Gefitinib and Radiation Therapy for Elderly Patients with Esophageal Squamous Cell Carcinoma: Preliminary Results of a Phase II Study.

Efficacy and safety of epigallocatechin-3-gallate in treatment acute severe dermatitis in patients with cancer receiving radiotherapy: a phase I clinical trial

Concurrent Radiotherapy with Gefitinib in Elderly Patients with Esophageal Squamous Cell Carcinoma: Preliminary Results of a Phase II Study

Concurrent erlotinib and radiotherapy for chemoradiotherapy-intolerant esophageal squamous cell carcinoma patients: results of a pilot study.

Molecular mechanism of epigallocatechin-3-gallate in human esophageal squamous cell carcinoma in vitro and in vivo.

Concurrent Chemoradiotherapy with Extended Nodal Irradiation And/or Erlotinib in Locally Advanced Esophageal Squamous Cell Cancer: Long-Term Follow-Up of a Randomized Phase 3 Trial